Humacyte logo

HumacyteNASDAQ: HUMA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 December 2020

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$584.88 M
-48%vs. 3y high
68%vs. sector
-vs. 3y high
-vs. sector
-122%vs. 3y high
3%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 2 min ago
$4.55+$0.14(+3.07%)

Dividend

No data over the past 3 years
$2.58 M$214.29 K

Analysts recommendations

Institutional Ownership

HUMA Latest News

Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMA
accesswire.com21 November 2024 Sentiment: -

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=112992&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA
accesswire.com21 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=112985&wire=1 or contact Joseph E. Levi, Esq.

January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA
accesswire.com21 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=112943&wire=1 or contact Joseph E. Levi, Esq.

HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
accesswire.com21 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period").

HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors With Large Losses in Humacyte, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
globenewswire.com21 November 2024 Sentiment: -

HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors With Large Losses in Humacyte, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Humacyte, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=112906&wire=1 or contact Joseph E. Levi, Esq.

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
prnewswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMA
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=112890&wire=1 or contact Joseph E. Levi, Esq.

Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues - Hagens Berman
accesswire.com20 November 2024 Sentiment: NEGATIVE

SAN FRANCISCO, CA / ACCESSWIRE / November 20, 2024 / Humacyte, Inc. (NASDAQ:HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v.

Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Humacyte, Inc.
prnewswire.com19 November 2024 Sentiment: NEGATIVE

SAN DIEGO , Nov. 19, 2024 /PRNewswire/ -- Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024. Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues.

What type of business is Humacyte?

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

What sector is Humacyte in?

Humacyte is in the Healthcare sector

What industry is Humacyte in?

Humacyte is in the Biotechnology industry

What country is Humacyte from?

Humacyte is headquartered in United States

When did Humacyte go public?

Humacyte initial public offering (IPO) was on 01 December 2020

What is Humacyte website?

https://www.humacyte.com

Is Humacyte in the S&P 500?

No, Humacyte is not included in the S&P 500 index

Is Humacyte in the NASDAQ 100?

No, Humacyte is not included in the NASDAQ 100 index

Is Humacyte in the Dow Jones?

No, Humacyte is not included in the Dow Jones index

When was Humacyte the previous earnings report?

No data

When does Humacyte earnings report?

The next expected earnings date for Humacyte is 21 March 2025